Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ambrx Biopharma (AMAM – Research Report), QuidelOrtho (QDEL – Research Report) and Aveanna Healthcare Holdings (AVAH – Research Report).
Ambrx Biopharma (AMAM)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Ambrx Biopharma on August 10 and set a price target of $29.00. The company’s shares closed last Friday at $14.25, close to its 52-week high of $16.86.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ambrx Biopharma with a $27.20 average price target.
See the top stocks recommended by analysts >>
QuidelOrtho (QDEL)
RBC Capital analyst Conor McNamara maintained a Buy rating on QuidelOrtho on August 9 and set a price target of $136.00. The company’s shares closed last Friday at $77.93.
According to TipRanks.com, McNamara is a 1-star analyst with an average return of
QuidelOrtho has an analyst consensus of Strong Buy, with a price target consensus of $128.50, which is a 66.6% upside from current levels. In a report issued on August 9, Craig-Hallum also maintained a Buy rating on the stock with a $168.00 price target.
Aveanna Healthcare Holdings (AVAH)
In a report issued on August 11, Ben Hendrix from RBC Capital maintained a Hold rating on Aveanna Healthcare Holdings, with a price target of $3.00. The company’s shares closed last Friday at $1.84.
According to TipRanks.com, Hendrix is a 1-star analyst with an average return of
Currently, the analyst consensus on Aveanna Healthcare Holdings is a Moderate Sell with an average price target of $2.03, which is a 12.8% upside from current levels. In a report issued on August 11, Truist Financial also maintained a Hold rating on the stock with a $2.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMAM:
- RBC Predicts 100% Gains for These 2 Stocks — Here’s Why They Have Strong Upside
- Ambrx Biopharma appoints Vaish as Chief Regulatory Officer
- Adobe upgraded, Salesforce downgraded: Wall Street’s top analyst calls
- Ambrx Biopharma initiated with an Outperform at RBC Capital
- Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023
